Literature DB >> 32345616

Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19.

Haralampos M Moutsopoulos1.   

Abstract

Entities:  

Keywords:  biological therapy; cryopyrin-associated periodic syndromes; cytokines

Year:  2020        PMID： 32345616     DOI： 10.1136/annrheumdis-2020-217562

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  14 in total

1.  COVID-19 in Immunocompromised Hosts: What We Know So Far.

Authors:  Monica Fung; Jennifer M Babik
Journal:  Clin Infect Dis       Date:  2020-06-27       Impact factor: 9.079

Review 2.  COVID-19 in Immunocompromised Hosts: What We Know So Far.

Authors:  Monica Fung; Jennifer M Babik
Journal:  Clin Infect Dis       Date:  2021-01-27       Impact factor: 20.999

Review 3.  Autoinflammatory and autoimmune conditions at the crossroad of COVID-19.

Authors:  Yhojan Rodríguez; Lucia Novelli; Manuel Rojas; Maria De Santis; Yeny Acosta-Ampudia; Diana M Monsalve; Carolina Ramírez-Santana; Antonio Costanzo; William M Ridgway; Aftab A Ansari; M Eric Gershwin; Carlo Selmi; Juan-Manuel Anaya
Journal:  J Autoimmun       Date:  2020-06-16       Impact factor: 7.094

Review 4.  Implications of COVID-19 in pediatric rheumatology.

Authors:  Ezgi Deniz Batu; Seza Özen
Journal:  Rheumatol Int       Date:  2020-06-04       Impact factor: 2.631

Review 5.  Exploring the magic bullets to identify Achilles' heel in SARS-CoV-2: Delving deeper into the sea of possible therapeutic options in Covid-19 disease: An update.

Authors:  Shikha Thakur; Bibekananda Sarkar; Arshad J Ansari; Akanksha Khandelwal; Anil Arya; Ramarao Poduri; Gaurav Joshi
Journal:  Food Chem Toxicol       Date:  2020-11-27       Impact factor: 6.023

6.  COVID-19 in Autoinflammatory Diseases with Immunosuppressive Treatment.

Authors:  Tatjana Welzel; Samuel Dembi Samba; Reinhild Klein; Johannes N van den Anker; Jasmin B Kuemmerle-Deschner
Journal:  J Clin Med       Date:  2021-02-05       Impact factor: 4.241

Review 7.  Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19.

Authors:  Jie Geng; Feng Wang; Zhiwei Huang; Xiaobo Chen; Yuliang Wang
Journal:  Cytokine       Date:  2021-04-17       Impact factor: 3.926

8.  Low symptomatic COVID-19 in an elderly patient with follicular lymphoma treated with rituximab-based immunotherapy: A case report.

Authors:  Stanisław Łącki; Kinga Wyżgolik; Michał Nicze; Sylwia Georgiew-Nadziakiewicz; Jerzy Chudek; Kamil Wdowiak
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337

Review 9.  Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection (SARSCoV-2): What is the Evidence?

Authors:  Eleftherios Pelechas; Vassiliki Drossou; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Mediterr J Rheumatol       Date:  2020-09-21

Review 10.  Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review.

Authors:  Amir Mohammad Beyzaee; Ghasem Rahmatpour Rokni; Anant Patil; Mohamad Goldust
Journal:  Dermatol Ther       Date:  2020-10-20       Impact factor: 3.858
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.